Covered recipient · General Payments record
ARISA E ORTIZ
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$265,484.02
- Reported across 174 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $19,005.00 | 3 |
| Grant | $17,500.00 | 1 |
| Travel and Lodging | $2,636.77 | 6 |
| Food and Beverage | $444.52 | 7 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $39,386.97 | 15 |
| REVANCE THERAPEUTICS, INC. | $199.32 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $4,525.00 | 01/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105159305 | CMS |
| ABBVIE INC. | $366.43 | 05/10/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1105159307 | CMS |
| ABBVIE INC. | $237.90 | 05/10/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1105159309 | CMS |
| ABBVIE INC. | $61.65 | 05/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159311 | CMS |
| ABBVIE INC. | $24.55 | 05/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159313 | CMS |
| ABBVIE INC. | $69.56 | 05/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159315 | CMS |
| ABBVIE INC. | $96.75 | 05/11/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1105159317 | CMS |
| ABBVIE INC. | $536.93 | 05/11/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1105159319 | CMS |
| ABBVIE INC. | $24.55 | 05/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159321 | CMS |
| ABBVIE INC. | $26.80 | 06/26/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1105159323 | CMS |
| ABBVIE INC. | $8,145.00 | 06/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105159325 | CMS |
| ABBVIE INC. | $64.89 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159327 | CMS |
| ABBVIE INC. | $17,500.00 | 07/18/2024 | Grant | Undisputed | 01/23/2026 | 1105159329 | CMS |
| ABBVIE INC. | $1,371.96 | 09/20/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1105159331 | CMS |
| ABBVIE INC. | $6,335.00 | 10/22/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105159333 | CMS |
| REVANCE THERAPEUTICS, INC. | $30.39 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147925921 | CMS |
| REVANCE THERAPEUTICS, INC. | $168.93 | 08/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147925923 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.